Biotheryx

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

UPPTHERA

The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.

Lycia Therapeutics

The company develops extracellular protein-degrading therapeutics for patients with autoimmune, inflammatory and allergic diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.